Business Wire

SMITHS-DETECTION

16.4.2024 08:01:30 CEST | Business Wire | Press release

Share
Smiths Detection launches cutting edge X-ray Diffraction scanner

Smiths Detection, a global leader in threat detection and security screening technologies, today announces that it has launched the SDX 10060 XDi, a ground-breaking X-ray scanner powered by diffraction technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415145550/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Smiths Detection's ground-breaking SDX 10060 XDi, powered by diffraction technology. (Photo: Business Wire)

X-ray Diffraction (XRD) is a powerful inspection technology offering highly accurate material discrimination and substance identification based on an object’s molecular structure. XRD is particularly suited to detecting constantly evolving compounds in powder, liquid or solid forms, such as ‘homemade’ explosives or narcotics, even for materials with similar densities.

Multi-level baggage and material handling operations and express forwarders are under pressure to screen huge volumes quickly and efficiently. The SDX 10060 XDi can transform this process by automating the resolution of potential explosive alarms, in turn improving both security and efficiency.

Due to its exceptional sensitivity, XRD technology can also be very effectively deployed to support customs agencies in screening for a range of contraband items including narcotics, helping to mitigate ever-growing threats to society.

Jerome de Chassey, President of Smiths Detection, commented: “We are immensely excited to announce the launch of the SDX 10060 XDi which marks a new era in security screening. Every minute of every day our threat detection and security screening technology helps to protect people and infrastructure, and this new development highlights our commitment to making the world a safer place. X-ray Diffraction will future-proof operations for a large variety of sectors, and we are proud to play a pivotal role in shaping the landscape of future threat detection.”

The SDX 10060 XDi can integrate seamlessly with existing material and baggage handling systems and is designed to meet ECAC Standard 3.1/3.2 and TSA 7.2 plus future regulations. Certification is underway.

See how XRD will enhance security here: https://youtu.be/CkoCpsrz97I

Jerome de Chassey, President, Richard Thompson, Vice President Marketing and Strategy, and Matthew Clark, Vice President Technology, will be present at Passenger Terminal Expo 2024 on 16 and 17 April, stand A145 in hall 5.1.

About Smiths Detection:

Smiths Detection is a global leader in threat detection and screening technologies for aviation, ports and borders, urban security and defence. With more than 70 years of field-tested experience, Smiths Detection deliver the solutions needed to protect society from the threat and illegal passage of explosives, prohibited weapons, contraband, toxic chemicals, biological agents, and narcotics – helping make the world a safer place.

For more information visit: http://www.smithsdetection.com/diffraction

About the SDX 10060 XDi:

The Smiths Detection SDX 10060 XDi leverages cutting-edge X-ray Diffraction (XRD) technology to offer unparalleled material discrimination and substance identification capabilities. By generating a unique 'diffraction fingerprint', it can accurately distinguish between substances with similar densities, making it exceptionally effective for identifying homemade explosives and narcotics in various forms. This advanced detection system is especially beneficial for high-volume, high-speed applications such as baggage screening at airports and parcel processing, where it enhances security and operational efficiency.

Discover how the SDX 10060 XDI can elevate your security screening operations here: https://www.smithsdetection.com/products/sdx-10060-xdi/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240415145550/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release

Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye